The collaboration will leverage Eris’s commercial presence in the diabetes segment and Natco’s manufacturing and regulatory ...
More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...
Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an ...
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling ...
International Equities added another 5% in the fourth quarter, finishing up over 30% for the year, the largest gain since ...
WYCKOFF, NJ - February 24, 2026 - PRESSADVANTAGE - RestoPros of Bergen-Passaic County has mobilized its certified ...
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results